These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 33953382)

  • 1. Pharmacogenetics to guide cardiovascular drug therapy.
    Duarte JD; Cavallari LH
    Nat Rev Cardiol; 2021 Sep; 18(9):649-665. PubMed ID: 33953382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
    Johnson JA; Cavallari LH
    Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacogenetics of antiplatelet agents: towards personalized therapy?
    Ahmad T; Voora D; Becker RC
    Nat Rev Cardiol; 2011 Aug; 8(10):560-71. PubMed ID: 21826075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of cardiovascular drugs.
    Saleh A; Al-Abcha A; Pereira N
    Curr Opin Cardiol; 2023 May; 38(3):207-214. PubMed ID: 37016993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk.
    Mauriello A; Ascrizzi A; Molinari R; Falco L; Caturano A; D'Andrea A; Russo V
    Genes (Basel); 2023 Nov; 14(11):. PubMed ID: 38003001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics in Stroke and Cardiovascular Disease: State of the Art.
    Ross S; Krebs K; Paré G; Milani L
    Stroke; 2023 Jan; 54(1):270-278. PubMed ID: 36325912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
    Shahin MH; Johnson JA
    Curr Opin Cardiol; 2013 May; 28(3):305-14. PubMed ID: 23478884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence.
    Gower MN; Ratner LR; Williams AK; Rossi JS; Stouffer GA; Lee CR
    Pharmgenomics Pers Med; 2020; 13():239-252. PubMed ID: 32821149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
    Shahabi P; Dubé MP
    Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetics of chronic cardiovascular drugs: applications and implications.
    Zineh I; Johnson JA
    Expert Opin Pharmacother; 2006 Aug; 7(11):1417-27. PubMed ID: 16859425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
    Cavallari LH; Mason DL
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation.
    Ong FS; Deignan JL; Kuo JZ; Bernstein KE; Rotter JI; Grody WW; Das K
    Pharmacogenomics; 2012 Mar; 13(4):465-75. PubMed ID: 22380001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular drugs and the genetic response.
    Dandona S
    Methodist Debakey Cardiovasc J; 2014; 10(1):13-7. PubMed ID: 24932357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of inpatient models of pharmacogenetics programs.
    Cavallari LH; Lee CR; Duarte JD; Nutescu EA; Weitzel KW; Stouffer GA; Johnson JA
    Am J Health Syst Pharm; 2016 Dec; 73(23):1944-1954. PubMed ID: 27864202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetics in cardiovascular disease: the challenge of moving from promise to realization: concepts discussed at the Canadian Network and Centre for Trials Internationally Network Conference (CANNeCTIN), June 2009.
    Joseph PG; Pare G; Ross S; Roberts R; Anand SS
    Clin Cardiol; 2014 Jan; 37(1):48-56. PubMed ID: 24105892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
    Roden DM
    Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.